PALISADE BIO, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PALI$1.13-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| License revenue | $— | $— | $500 | $— |
| Operating expenses: | ||||
| Research and development | 10,579 | 1,394 | 24,376 | 4,019 |
| General and administrative | 5,121 | 1,528 | 14,270 | 4,056 |
| Total operating expenses | 15,700 | 2,922 | 38,646 | 8,075 |
| Loss from operations | (15,700) | (2,922) | (38,146) | (8,075) |
| Other (expense) income: | ||||
| Interest expense | — | (5) | (1) | (8) |
| Other income, net | 1,077 | 59 | 3,350 | 201 |
| Total other income, net | 1,077 | 54 | 3,349 | 193 |
| Net loss | $(14,623) | $(2,868) | $(34,797) | $(7,882) |
| Basic and diluted weighted average shares used in computing basic and diluted net loss per common share | 212,027,787 | 7,473,898 | 211,035,838 | 5,702,050 |
| Basic and diluted net loss per common share | $(0.07) | $(0.38) | $(0.16) | $(1.38) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.